Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01)

The summary for the Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01)
	CFDA Number:	93.242
	CFDA Description:	Mental Health Research Grants
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PAR-08-160
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Apr 25, 2008
	Creation Date:	Dec 05, 2008
	Original Closing Date for Applications:	Feb 22, 2012
	Current Closing Date for Applications:	Feb 22, 2012
	Archive Date:	Mar 24, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: -Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), invites investigator-initiated research grant applications for studies examining the adverse metabolic effects (i.e., obesity and diabetes) of psychotropic medications in animal models and across the human lifespan (including pediatric, adult and geriatric populations). Applications responsive to this FOA should focus on 1) increasing the understanding of the nature, rates, and pathophysiology of adverse metabolic effects of psychotropic medications, 2) elucidating biomedical and psychosocial risk factors for the development of metabolic adverse effects of psychiatric therapeutics, and 3) develop interventions to prevent and/or mitigate metabolic adverse effects across the lifespan. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/par-08-160.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R21); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R03); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R03); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R34); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R34); • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R42]); • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (STTR [R41/R42]); • Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Screening Cent...